CAR-T Meeting 2024 | Bendamustine vs Flu/Cy lymphodepletion prior to CAR-T: reducing rates of toxicity and infection
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses retrospective comparisons of bendamustine lymphodepletion and standard fludarabine/cyclophosphamide (Flu/Cy) lymphodepletion prior to CAR T-cell therapy in patients with large B-cell lymphoma (LBCL) and follicular lymphoma (FL). These analyses determined that bendamustine lymphodepletion results in comparable responses to Flu/Cy while being associated with lower rates of toxicity and infection. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Inventor: CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity, and
viTToria biotherapeutics;
Research Funding: AbClon, Beckman-Coulter, ONI, Lumicks, viTToria bio;
DSMB: PeproMene;
Consultancy/Honoraria: GLG, Guidepoint;
Advisory Board: viTToria bio, AbClon, BMS, Sana, GSK, Bayer;
Scientific Founder: viTToria biotherapeutics.
